Epigenetic regulation of immune cell types could be critical for the development and maintenance of autoimmune diseases like rheumatoid arthritis
Introduction
Rheumatoid Arthritis (RA) is the most common autoimmune disease of the joints, with a worldwide prevalence of $1% (1) . In RA, cells from the immune system are aberrantly activated, leading to the destruction of the cartilage and bone (2) . The etiology of the disease is believed to combine diverse risk factors including genetic and epigenetic variation (3) . Genome-wide association studies have successfully identified more than 100 DNA sequence polymorphisms associated with RA (4) . Despite these advances, much of the causality that underlies the disease still remains unknown. The identification of epigenetic variation in key cell types associated with RA could provide valuable insights into the biological mechanisms that initiate and perpetuate the disease.
In RA, multiple innate and adaptive immune cells participate in the chronic inflammation of the synovial joint (2) . CD4 þ T cells, in particular Th17 and Treg subsets (5) , are central mediators in RA pathology and, in the last years, much has been advanced in the characterization of these cell types. B cells, are also a key cell type in RA pathology but, comparatively, much less is known on the biological mechanisms associated with disease (6) . In RA, patients characteristically express antibodies raised against self antigens. Anti-citrullinated peptide antibodies (ACPA) are present in the plasma of >75% of patients, and are currently the most specific diagnostic biomarkers (7, 8) . Also, antibodies raised against the Fc region of IgG, commonly known as rheumatoid factor, are present in $80% of patients and, although less specific than ACPA, they are also useful as diagnostic and prognostic markers (8, 9) . More recently, additional types of autoantibodies have been identified, some of which, like ACPA, might precede the onset of RA (10) . A direct evidence of the importance of this cell type in the disease etiology is that the transient depletion of B cells is an efficacious treatment for RA (6, 11) . To date, however, the regulatory mechanisms by which this cell type contributes to the disease have not been elucidated.
The success of GWAS in the discovery of new DNA polymorphisms associated with disease has been driven by the use of replication strategies (12) . In EWAS, however, the use of replication studies independent cohorts is still not widespread and therefore, confirmatory evidence is still needed in many cases. In RA, despite few studies have provided independent validation of the results, there is nonetheless consistent evidence demonstrating the implication of epigenetics in the etiology of the disease (3) . Very recently, an EWAS of cultured synovial fibroblasts has shown that methylation patterns not only clearly distinguish RA patients from controls, but they are also specific of the type of joint from which they are isolated (13) . The analysis of genomic methylation from whole blood DNA has also been able to robustly identify methylation variation associated with the disease (14) . Using tissues like blood to identify relevant epigenetic patterns is, however, hampered by the cell-type heterogeneity present in the biological sample (15) . B cells, for example, amount to less than 5% of the leukocytes in whole blood. The presence of complex mixtures can severely impact the ability to identify relevant methylation variation and, consequently, the analysis of specific cell types is strongly recommended (16) .
In this study, we present the results from an EWAS for RA performed on B lymphocytes. The differential methylation identified using the Illumina HumanMethylation BeadChip in the discovery cohort was tested for replication on two independent case-control samples. An additional case-control sample of B cells from systemic lupus erythematosus, an autoimmune disease were the role of this cell type is also central, was used to determine the association and similarity with the RA epigenetic markers.
Results

Discovery analysis: genome-wide analysis of differential methylation in B cells
An EWAS from B cells was done in the discovery cohort (N ¼ 50 patients and N ¼ 75 healthy controls). Clinical and epidemiological characteristics of this cohort are shown in Table 1 . After quality control analysis, DNA methylation levels on 468,640 CpG sites from N ¼ 49 RA patients and N ¼ 73 controls were available for analysis. There were no differences between patients and controls in age or gender.
The linear regression models fitted to test the differences in DNA methylation levels between RA patients and controls showed 64 significant CpG sites after false-discovery rate (FDR) correction (q < 0.05, Supplementary Material, Table S1 ).
To further characterize the biological mechanisms associated with B cell epigenetics in RA, we performed a pathway analysis. Pathways with too low or too large number of genes (N ¼ 24 pathways) were excluded. A total of 1,053 biological pathways were tested for differential methylation in B cells. Six pathways were found to be significantly associated with RA after multiple testing correction ( Table 2) .
Analysis of B cell type heterogeneity
B cells in whole blood are divided into two major subsets: naive and memory B cells. In order to determine the presence of different proportions of B cell subtypes in cases and controls, we used the genome-wide methylation data to estimate the Fig. S1 ).
Replication analysis of the novel CpG sites in RA
The 64 CpG sites associated with RA in the discovery stage were tested for replication in an independent cohort from the same geographic region (N ¼ 30, Catalonia, Northeast of Spain). After quality control analysis, N ¼ 14 patients and N ¼ 15 controls were available for replication analysis. Clinical and epidemiological characteristics of this cohort are shown in Table 1 . There were no differences between patients and controls in age or gender.
The regression analysis between methylation levels on B cells and RA replicated the association of 10 CpG sites with the disease (P < 0.05, Table 3 ). In all genomic loci, except for TNFSF10 CpG cg03055671, DNA methylation levels where higher in B cells from RA patients compared to healthy controls. The association between Regulation of signaling by CBL pathway with RA was also replicated (P ¼ 0.029, Fig. 1) .
In order to provide additional evidence of association between the replicated CpG sites and RA, we analyzed a casecontrol cohort from a different population (N ¼ 24, United Kingdom). After quality control analysis, N ¼ 11 cases and N ¼ 11 controls were available for replication. Clinical and epidemiological characteristics of this cohort are shown in Table 1 . In this cohort, there were no differences between patients and controls in gender, but RA cases were significantly older than controls (P ¼ 0.00034). As in the discovery and Spain replication cohorts, adjustment for age, gender and PCs of variation was performed.
The linear regression analysis between methylation levels on B cells and RA replicated the association between CD1C (cg18972751, P ¼ 0.012, P combined ¼ 2.26 x 10 À9 ), TNFSF10
(P ¼ 0.028, cg03055671, P combined ¼ 1.67 x 10 À8 ) and DHRS12
) CpG sites with RA (Supplementary Material, Table S2 ). CBL signaling pathway association with RA was not replicated in this cohort.
Replication analysis of the novel CpG sites in systemic lupus erythematosus (SLE)
The role of B cells in SLE etiology is central and has been known for many years (17) . Like RA, SLE patients produce autoantibodies, although to a much more larger diversity of self-antigens. Both autoimmune diseases also share common genetic risk factors. We therefore hypothesized that the B cell altered functionality observed in both diseases could also be caused by common epigenetic regulatory mechanisms. In order to test this hypothesis, we analyzed the association between the 10 RA-associated CpGs with SLE. After quality control analysis, N ¼ 56 SLE patients and N ¼ 47 controls from the USA were available for replication. The regression analysis replicated the association at 9 out 10 of the RA-associated CpG loci (Table 4) . In all associated CpG sites, the changes in DNA methylation of SLE B cells occurred in the same direction as in RA. Regulation of signaling by 
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Database, reference biological database from where the pathway annotation was obtained; # Genes, number of genes in the pathway; # CpGs, number of CpG sites mapping to the pathway genes; P-value adjusted for age, sex and the main PCs of variation; P-value corr ¼ P-value after multiple testing correction. The 10 CpG sites significantly replicated (P < 0.05, same methylation change) in the Spain validation cohort are shown. DBeta, absolute difference in the mean beta values (effect size) between cases and controls expressed as percentage; Combined P, P-value combining discovery and replication cohorts.
CBL pathway association with SLE was also replicated (P < 0.001).
Genetic variation association with RA risk
From the 10 differentially methylated CpGs, we identified three highly significant cis mQTLs at TNFSF10, IRF8 and ACSF3 loci that were associated with RA risk (Table 5 ).
Discussion
In this study, we aimed to identify variation in CpG methylation in B cells associated with RA. Using two independent validation datasets, we found hypermethylation at CD1C and hypomethylation at TNFSF10 genes to be associated with RA. The proteins encoded by these two genes are strongly associated with the immune cell response, suggesting new biological mechanisms for disease initiation and perpetuation. CD1C encodes for an MHC class I-like glycoprotein that mediates lipid antigen presentation to T cells (18) . Compared to the other three members of the CD1 family, CD1C shows a highly promiscuous antigen-binding behavior, with the ability to form antigenic complexes with different single and two alkyl-chain lipids (19) , glycolipids as well as lipopeptides (20) . Of relevance, these lipid molecules can have a foreign origin (21) but can also can be self antigens (22) , suggesting that presentation by this protein could lead to autoimmune reactivity. CD1C has also shown to be the main activating mechanism for TCR cd T cells (23) . This T cell subtype acts as sentinel in many tissues and activates in response to self antigens. Upon activation, cd T cells produce interleukin 17, a powerful proinflammatory cytokine that has been associated with the establishment of several autoimmune diseases, including RA (24) . We found suggestive evidence of a positive correlation between methylation CD1C CpG -cg18972751-and CD1C mRNA expression levels (Supplementary Material, Fig. S8 ). While CpGs in islands particulary in promoter regions are strongly associated with gene expression inhibition, isolated CpGs located in other regions can be associated both to over-or downregulation of gene expression (25) . Based on our findings, CD1C overexpression in B cells and subsequent presentation to cd T cells could be increasing the likelihood of self-antigen reactivity in RA. Supporting this hypothesis, CD1Cþ B cell activation of cd T cells has shown to induce IgG isotype switching in SLE (26) . Functional testing of CD1Cþ B cells in RA should be performed to identify if this mechanism of antibody specialization is similarly altered in RA.
TNFSF10 (also known as TRAIL) encodes for a cytokine that belongs to the TNF ligand family. It can potentially bind to five different receptors (27) , inducing an apoptosis program in tumor cells. Blocking TNFSF10 systemically has shown to improve collagen-induced arthritis in mice (28) and it has also shown to be an important mediator of cell death of activated synovial fibroblasts in RA (29, 30) . To date, however, the specific role of this gene in B cell activity is not clear (31) . Studies on malignant B cells have shown an upregulation of this ligand, and this has been also functionally associated to an inactivation of bone forming cells leading to bone erosion, which is also a major feature in RA (32) . In vitro activation of B cells with CpG-containing oligonucleotides -a major immunogenic signal-has shown to lead to high levels of TNFSF10 (33) . Analyzing the association between the associated CpG methylation and TNFSF10 using gene expression data from the reference B cell subsets (34) , there is suggestive evidence of association between hypomethylation and increased gene expression ( Supplementary  Material, Fig. S6 ). Furthermore, using available gene-expression data on isolated B cells from RA and SLE patients and healthy controls (GEO dataset GSE4588), there is evidence of a highly significant overexpression of TNFSF10 in both autoimmune diseases compared to controls (P < 0.0005, Supplementary Material, Fig. S7 ). Together, this evidence supports that the observed hypomethylation in RA leads to TNFSF10 overexpression. The functional implications of an increase in this death-inducing factor in B cells and its relation to disease are, to date, unclear and will require future research. Using two independent replication cohorts, we provide robust validation of the CpG sites associated with B cell epigenetics in RA. There are, however, several genomic regions that show substantial evidence of association and it is likely that analysis using additional samples could corroborate their association with the disease. One of such loci is PARVG, which despite not being replicated in the UK cohort, reached a genome-wide level of significance with RA after combining all three cohorts (P ¼ 6.34 x 10
À9
). To date, very little is known on the biological role of this gene. Gene expression profiling in human tissues shows a preferential expression of PARVG in immune cell types B lymphocytes (Supplementary Material, Figs S4A and B) . Also, functional prediction strongly suggests that PARVG participates in B cell regulation activities (B cell receptor signaling activity (GO:0050853) P ¼ 2.33Â10 À20 and Regulation of B cell differentiation (GO:0045577) P ¼ 1.6Â10 À19 , Supplementary Material, Table S2 ). Future studies will be needed to confirm the role of PARVG in B cell activity and how alterations in this biological mechanism might contribute to RA. In this study, we also analyzed differential methylation of B cells at the pathway level. We replicated the differential methylation at Regulation of signaling by CBL signaling pathway in the Spain cohort as well as the SLE case-control cohort. Compared to other previous studies that have performed pathway-based analysis, we have used an approach that corrects for the differences in the number of CpG sites associated with each gene and estimates significance via permutation. This way, only independent signals at each gene from the pathway are evaluated, thereby reducing the presence of false positives (35) . CBL pathway integrates different genes (n ¼ 18 in the Reactome database) that participate in the signal transduction in various cell types including immune cells (36) . One of the best studied CBLassociated signaling transduction systems is the B Cell Receptor (BCR) signaling, where CBL interacts with B-cell Linker gene (BLNK) to promote BCR-complex degradation and therefore provides a negative regulation mechanism of B cell activation (37) . Mouse CBL-knockouts have shown impaired B cell tolerance and subsequent development of autoimmune reactions (38) . In particular, the lack of CBL has shown to reduce the rate of maturation of B cells, thereby increasing the likelihood of immature self-reactive cells to escape anergy. The deregulation of this key signaling pathway in B cells could therefore lead to an inadequate immunological response and contribute to the perpetuation of autoimmunity in RA.
SLE is an autoimmune disease where the role of B cells is highly predominant, with the production of a large diversity of autoantibody responses. A previous genome-wide study on B cell methylation in SLE showed a strong association with genes related to interferon (IFN)-mediated immunity (39) . Here, we found that 9 out of the 10 CpGs associated with RA in B cells -CD1C, TNFSF10, PARVG, NID1, DHRS12, ITPK1, ACSF3, TNFRSF13C and intergenic region chr10p12.31-are also associated with SLE. Importantly, the methylation changes in SLE occurred in the same direction as in RA. To our knowledge, this is the first evidence of shared methylation variation in B cells between both diseases. Furthermore, examining the methylation sites previously reported to be highly significantly associated with SLE (n ¼ 166 CpGs) in our discovery cohort, we find nominal association (P < 0.05) on 31% of these loci with RA, from which 98% occur in the same direction as originally identified in SLE (18% hypermethylated and 82% hypomethylated, Supplementary Material, Table S3 ). Combined, our results on RA and SLE B cell DNA methylation support the presence of common epigenetic mechanisms governing the activity of this cell type in the two autoimmune diseases.
GWAS have shown that RA and SLE have common genetic risk variation, particularly in genes from the TNF -TRAF1, TNFAIP3, CD40, TNIP1-and Interferon -IRF5, IRF8-cytokine pathways (40) (41) (42) (43) . Three of the replicated CpG sites belong to loci from these two immune pathways: TNFSF10, TNFRSF13C and IRF8. From these, we have found suggestive evidence of mQTLs regulating the methylation levels of TNFSF10 and IRF8 CpGs and that are also associated with RA risk. This evidence supports the role of these methylation sites as mediators of disease susceptibility. The corroboration of these CpG-based mediation in disease risk, however, will require the use of specific, causal inference tests (44) . Also, while cell-specific mQTLs can be identified even in complex cell mixtures like blood (14) , a comprehensive determination of these loci will inevitably require isolation and analysis on the target cell type.
A limitation of our study is the relatively small sample of the study cohorts. Based on the effect sizes and variation of the CpGs associated in the discovery cohort, only association at CD1C had !80% power of replication in the Spain validation cohort (Supplementary Material, Table S4 ). However, including an additional cohort from a different population (UK) under different clinical settings and different environmental exposures, further supported the evidence of association at three out of the 10 CpG sites -cg18972751 (CD1C), cg03055671 (TNFSF10) and cg07285641 (DHRS12)-replicated in the Spain cohort. Importantly, here we analyzed the methylation pattern of a specific cell type instead of a whole tissue. While this approach is more costly and therefore limits the ability to recruit larger cohorts of individuals, it will be the only way to identify specific epigenetic patterns that are relevant to the disease (45) .
In summary, this study discovered and replicated 10 loci (CD1C, TNFSF10, PARVG, NID1, DHRS12, ITPK1, ACSF3 and TNFRSF13C and 2 intergenic regions) associated with RA in B cells in two Spain cohorts. Using and additional UK case-control cohort provided further evidence for the association between CD1C, TNFSF10 and DHRS12 loci with RA. Differential methylation at CD1C, TNFSF10, PARVG, NID1, DHRS12, ITPK1, ACSF3, TNFRSF13C and intergenic region chr10p12.31 was also replicated in the SLE cohort. The findings of this study suggest new biological mechanisms that could be associated with RA pathology, and also show the presence of common epigenetic changes in B cells from two autoimmune diseases. This former result supports that, similar to genetic risk, epigenetic variation in key cell types could be shared in autoimmunity.
Materials and Methods
Study cohorts and sample collection
Discovery cohort. This study was approved by the Institutional Review Board of the Vall d'Hebron University Hospital (HUVH, Barcelona, Spain), and informed consent was obtained from all participants. In the discovery stage, CD19þ B cells were purified from whole blood samples of 50 patients with RA and 75 healthy controls. RA patients were recruited from the rheumatology outpatients clinics from the HUVH. All RA patients satisfied the ACR 1987 classification criteria for RA and had >2 years of follow-up since diagnosis (46) . Control individuals were approached at the HUVH, were confirmed to be free of any autoimmune disease, including their first and second-order relatives. Table 1 summarizes the clinical and epidemiological criteria of the patients and controls from in the discovery stage.
From each participant, 20mL of whole blood was extracted and CD19þ B cells isolated by positive selection using the CD19 Dynabeads Pan B immunomagnetic separation system (Life Technologies). A fraction ($10%) of the purified CD19þ B cells was used for cell cytometry quantification. The remaining cells were stored at À80 C until DNA extraction.
In order to assess the purity of the isolated cells using flow cytometry, cells were first released from the immunomagnetic beads using Detachabead (Life Technologies). Cells were then stained with anti-human CD19-FITC antibody (eBioscience) and the nuclear marker bisbenzimide H33342 trihydrochloride (Sigma-Aldrich). Samples were then analyzed using a Gallios Flow Cytometer (Beckman Coulter), and the data were analyzed using the Summit software v4.3 (Dako Colorado). An average (6SD) purity of 95.6% (64.2) was obtained.
Validation cohorts. In the validation stage, 15 RA patients and 15 matched healthy controls were recruited. Patients and controls from the Spain replication cohort were recruited from the HUVH Hospital (Barcelona, Spain). CD19þ B cell isolation and genomic DNA purification were performed following the same procedure as in the discovery stage. An average (6SD) purity of 98.0% (61.4%) was obtained. The characteristics of the patients and controls from the Spain validation cohort described in Table 1 .
In order to provide additional evidence for the methylation changes associated with RA, we analyzed an additional casecontrol dataset from the UK population (47) . This dataset included 12 female patients that satisfied the ACR diagnostic criteria for RA and 12 female healthy controls. Genome-wide methylation data were obtained using the Illumina methylation450K platform. CD19þ B cells were also purified using positive selection, and an average purity of 89.5 (611.3%, RA) and 90.9 (6 9.5%, controls) was obtained. The characteristics of the patients and controls from the UK validation dataset are described in Table 1 .
SLE replication cohort. In order to test whether the B cell methylation pattern associated with RA was also associated with SLE, we used a publicly available genome-wide methylation dataset on 56 SLE patients and 47 controls generated using the same microarray technology (Illumina methylation450K)(GEO accession: GSE59250) (39) . In this study, CD19þ B cells were purified using positive selection (>95% purity in all samples). The characteristics of the patients and controls from the SLE replication dataset are described in Supplementary Material, Table S5 (Supplementary Methods).
Genome-wide DNA methylation analysis
Genomic DNA was extracted from the discovery (N ¼ 125) and validation (N ¼ 30) B cells using the DNeasy Blood & Tissue kit (Qiagen). DNA methylation levels for the discovery cohort and the Spain validation cohort were measured using the Infinium HumanMethylation450 array (Illumina, San Diego, USA). 500 ng of each DNA sample was treated with sodium bisulfite (Zymo EZ DNA) prior to standard Illumina amplification, hybridization, and imaging steps. Raw data intensity files from all four casecontrol cohorts were processed as described previously (39) . Briefly, CpG probes with detection P-values > 0.01 and probes affected by SNP variants were filtered out, batch effects were corrected using ComBat (48) , and Infinium chemistry corrections were made by second order polynomial estimates. In order to avoid introducing batch effects, each case-control cohort was processed simultaneously. Batches were, instead, defined as a single array consisting of 12 samples, as described previously (49) . In order to discard individuals with an outlier methylation profile, samples with an average correlation with the remaining samples r 2 < 0.95 were considered outliers and discarded from downstream analyses (n ¼ 3 discovery cohort, n ¼ 1 Spain validation cohort, n ¼ 2 UK validation cohort, n ¼ 0 SLE cohort). Genome-wide data methylation processing was performed using the R statistical language (50) .
Estimation of B cell subtype proportions
B cells in whole blood, include two main cell subtypes: CD19 þ IgD þ CD27-(naive) B cells and CD19 þ IgAþ/IgD þ CD27þ (memory) B cells. To estimate the frequency of each subtype in the samples, we used genome-wide methylation data from purified naive and B cells generated by the BLUEPRINT epigenomics consortium using the Infinium HumanMethylation450 array (Illumina, San Diego, USA) (34) . Using a maximum likelihood approach, we estimated the percentages of naive and memory B cells in each sample. The methodological details of this analysis are included in the Supplementary Material.
Identification of differentially methylated CpG sites
Multivariate linear regression in the discovery stage was used to identify methylation changes associated with RA as described previously (39) . Age, gender and the four principal components of variation were used as covariates in the regression model. CpGs with a False Discovery Rate (FDR) q-value < 0.05 were considered significant. Details on the principal component analysis are described in the Supplementary Material. Replication of the 64 CpGs identified in the discovery stage was performed in the Spain RA case-control cohort using the same linear regression approach. Differentially methylated sites were considered validated if the association P-value < 0.05. Combined P-values were calculated using Fisher's method. The association testing of the 10 replicated CpG sites replicated in the Spain cohort was performed in the UK cohort fitting the same linear model. One-sided P-values were calculated in this second replication analysis. All statistical association analyses were performed using the R statistical language (50) .
Association analysis in the SLE case-control cohort was performed using the same multivariate linear regression analysis, including age, gender and the main PCs of variation as covariates.
Analysis of differentially methylated pathways
Pathway analysis approaches using genome-wide methylation data can be highly informative of the main biological processes that underlie a particular trait or disease. However, these approaches can be highly biased in EWAS due mainly to the uneven CpG coverage of genes (35) . This analytical problem has been previously identified in the pathway analysis of GWAS. While different approaches have been developed for GWAS data, there has been much less development for epigenetic genomewide studies. Permutation-based approaches, while computationally costly, have shown to have a superior power to robustly identify new biological pathways associated with disease (51) . In particular, the set-based test implemented in PLINK GWAS analysis tool has shown to perform significantly better than other alternative approaches (52) . In order to exploit the power of this approach for EWAS, we have developed a new association method (Pathway Methylation Analysis, PMA) based on the PLINK set-based analysis (Supplementary Material, Fig. S5 ). Briefly, CpGs are first mapped to genes (þ/-2 flanking kb). For each CpG site, association with the outcome of interest is tested using multivariate linear regression with adjustment for relevant covariates (here, age, gender and the first principal components of variation). After association testing, neighbouring probes at each locus showing significant correlation (r 2 > 0.2) are identified and filtered out. With this step, only truly independent association signals at each pathway gene are included, and redundant signals are excluded. Finally, an association statistic per each pathway is calculated by averaging over the most significant and independent CpGs. In order to establish the statistical significance of each pathway, an empirical P-value is calculated using a permutation approach (N > 10,000 permutations). The PMA algorithm was implemented using the R statistical language and is available as an open-source software package (http://www.urr.cat/PMA). The biological pathways were obtained from the Biocarta, KEGG and Reactome reference databases available at the MSigDB repository (March 2016) (53) . A total of 1,077 pathways were available. Following previous studies, pathways with very low (n < 10) or very large (n > 300) number of genes were excluded to potential biases associated with extreme sizes (n ¼ 24, 2.2%) (54) . Finally, 1,053 biological pathways were selected for differential methylation analysis in B cells in RA.
Power calculation
To estimate the power of replication of the CpGs in the Spain validation cohort (N ¼ 30), we used a resampling basedapproach. Using the methylation value (beta value) distribution from the discovery cohort, we used resampling and permutation (N ¼ 10,000) to estimate the power of replication of the CpGs associated with RA in the discovery cohort (N ¼ 64, q < 0.05). Using this approach, 60 CpGs (94%), 25 CpGs (39%) and 3 CpGs (5%) had >50%, >60% and >70% power of replication respectively (Supplementary Material, Table S4 ). Only 1 CpG (cg18972751, CD1C) had >80% power of replication according to the sample size of the Spain validation cohort.
Genetic variation association with RA risk
Methlyation changes can mediate the association between DNA variants and disease risk. In order to identify this type of association, we identified Single Nucleotide Polymorphisms (SNPs) associated significantly associated with the methylation levels in all 10 replicated CpGs in this study. For this objective, we used the mQTLdb database (http://www.mqtldb.org/; date last accessed: February 1, 2017) , an open-access repository of methylation quantitative trait loci (mQTLs) associated with methylation levels of blood samples across the genome. This mQTL database has been generated using genome-wide methylation levels determined on a large healthy individual cohort (n > 2,000) using the same array platform (Illumina Methylation 450K) and imputed genetic data (n ¼ 8,074,398 loci) based on genome-wide genotyping using HumanHap550 and Human660 quad arrays (Illumina) (55) . Cis mQTLs associated with the methylation levels at the 10 CpGs associated with RA and at <100kb distance were identified (25) . In order to reduce the selection of false positives, we applied a significance threshold of a ¼ 1Â10 À7 . A total of n ¼ 201 significant mQTLs were identified. From these, association with RA risk was further evaluated using genetic association results from a recent large transethnic GWAS meta-analysis on RA (4). This meta-analysis study includes genetic association results on 14,361 RA patients and 43,923 controls from European ancestry and 4,873 cases and 17,641 controls from Asian ancestry.
Accession numbers
Methylation data have been submitted to the Gene Expression Omnibus (GEO, http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE87095. The BLUEPRINT methylation and gene expression data on whole blood naive and memory B cell subtypes are available at the European Genome-Phenome Archive (EGA, https://ega.crg.eu/), with accession numbers EGAD000 10000716 and EGAD00010000718, respectively.
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Supplementary Material is available at HMG online.
